Vistabex

Phase 2Small molecule

AAzienda Ospedaliera Universitaria Integrata Verona

Vistabex is one of 4 small molecule programs targeting Facial Paralysis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Facial ParalysisActive, not recruiting

Facial ParalysisPhase 2

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Facial Paralysis

#DrugCompanyPhaseTrials

Chemodenervation

UUniversity of California, Los Angeles

Approved

1 2

Mecobalamin

Eisai

Preclinical

1 3

Botox

RRevance Therapeutics, Inc.

Preclinical

—4

Vistabex

AAzienda Ospedaliera Universitaria Integrata Verona

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Facial Paralysis1 trial

Onabotulinumtoxin A and Hyaluronic Acid Fillers in the Treatment of Facial Paralysis

Unknown status·AAzienda Ospedaliera Universitaria Integrata Verona·Phase 2·NCT05012566·70 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Vistabex. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Vistabex compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Vistabex. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Azienda Ospedaliera Universitaria Integrata Verona company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAzienda Ospedaliera Universitaria Integrata Verona

Vistabex

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Facial Paralysis1 trial

References

Drug Info

Quick Facts

Related News